from its AdoXLong™ Platform at ObesityWeek® 2026.
Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of metabolic diseases including diabetes and obesity, today announces that the lastest preclinical data on its AdoXLong™ platform will be presented as a poster at the ObesityWeek® 2026, taking place in
Washington, USA, from November 14 – 17, 2026.
Poster Details:
Title: AdoXLong: A Long-Acting Peptide Platform Enabling Once-Monthly Administration of Incretins
Poster Presentation: Saturday, November 14, 2026, 7:30 – 8:30 pm EST (Washington, USA)
Session: Gut Peptides, Appetite Signaling & Novel Therapeutics
Presenter: Martin Gaudier, PhD
